Affected Systems |
|
|
|
|
|
|
|
|
|
|
|
cardiovascular system
|
|
|
|
|
|
|
|
|
√
|
|
abnormal liver sinusoid morphology
|
|
|
|
|
|
|
|
|
√
|
|
abnormal hepatic vein morphology
|
|
|
|
|
|
|
|
|
√
|
|
cellular
|
|
|
|
|
|
|
|
|
√
|
|
abnormal cell cycle
|
|
|
|
|
|
|
|
|
√
|
|
endocrine/exocrine glands
|
|
|
|
√
|
|
|
√
|
|
√
|
|
abnormal bile duct development
|
|
|
|
√
|
|
|
|
|
|
|
abnormal intrahepatic bile duct morphology
|
|
|
|
|
|
|
|
|
√
|
|
bile duct proliferation
|
|
|
|
|
|
|
√
|
|
|
|
dilated bile duct
|
|
|
|
|
|
|
√
|
|
|
|
growth/size/body
|
|
√
|
N
|
√
|
|
|
|
√
|
|
|
growth/size/body region phenotype
|
|
|
N
|
|
|
|
|
|
|
|
decreased body weight
|
|
√
|
|
|
|
|
|
|
|
|
liver cyst
|
|
|
|
√
|
|
|
|
√
|
|
|
homeostasis/metabolism
|
√
|
√
|
√
|
|
|
|
|
|
|
√
|
increased circulating glucose level
|
|
√
|
|
|
|
|
|
|
|
|
decreased liver glycogen level
|
|
|
|
|
|
|
|
|
|
√
|
abnormal lipid homeostasis
|
|
√
|
|
|
|
|
|
|
|
|
decreased liver triglyceride level
|
|
√
|
√
|
|
|
|
|
|
|
|
decreased incidence of tumors by chemical induction
|
√
|
|
|
|
|
|
|
|
|
|
increased incidence of tumors by chemical induction
|
√
|
|
|
|
|
|
|
|
|
|
liver/biliary system
|
√
|
√
|
√
|
√
|
|
|
√
|
√
|
√
|
√
|
abnormal bile duct development
|
|
|
|
√
|
|
|
|
|
|
|
bile duct proliferation
|
|
|
|
|
|
|
√
|
|
|
|
dilated bile duct
|
|
|
|
|
|
|
√
|
|
|
|
abnormal hepatoblast morphology
|
|
|
|
|
|
|
|
|
√
|
|
decreased hepatoblast number
|
|
|
|
|
|
|
|
|
√
|
|
abnormal liver morphology
|
|
|
|
√
|
|
|
|
|
|
√
|
abnormal liver sinusoid morphology
|
|
|
|
|
|
|
|
|
√
|
|
abnormal intrahepatic bile duct morphology
|
|
|
|
|
|
|
|
|
√
|
|
liver cyst
|
|
|
|
√
|
|
|
|
√
|
|
|
decreased liver glycogen level
|
|
|
|
|
|
|
|
|
|
√
|
decreased liver triglyceride level
|
|
√
|
√
|
|
|
|
|
|
|
|
abnormal liver development
|
|
|
|
|
|
|
|
|
|
√
|
abnormal hepatic cord morphology
|
|
|
|
|
|
|
|
|
√
|
|
abnormal hepatocyte morphology
|
|
|
|
|
|
|
|
|
|
√
|
dissociated hepatocytes
|
|
|
|
|
|
|
|
|
|
√
|
decreased liver weight
|
|
√
|
|
|
|
|
|
|
|
|
increased hepatocellular carcinoma incidence
|
√
|
|
|
|
|
|
|
|
|
|
abnormal bile secretion
|
|
|
|
|
|
|
√
|
|
|
|
mortality/aging
|
|
|
|
|
|
|
|
|
√
|
|
lethality throughout fetal growth and development, incomplete penetrance
|
|
|
|
|
|
|
|
|
√
|
|
neoplasm
|
√
|
|
|
|
|
|
|
|
|
|
decreased incidence of tumors by chemical induction
|
√
|
|
|
|
|
|
|
|
|
|
increased incidence of tumors by chemical induction
|
√
|
|
|
|
|
|
|
|
|
|
increased hepatocellular carcinoma incidence
|
√
|
|
|
|
|
|
|
|
|
|
normal phenotype
|
|
|
|
|
√
|
√
|
|
|
|
|
no abnormal phenotype detected
|
|
|
|
|
√
|
√
|
|
|
|
|